Early prostate cancer diagnosis and therapy

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 41-64

  Glodé, L Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; BLOOD; CANCER STAGING; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE TUMOR; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; TIME; TREATMENT OUTCOME;

ADULT; AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033631136     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Stanford JL, Stephenson RA, Coyle LM, et al: Prostate Cancer Trends 1973-1995. Bethesda, Md, SEER Program, National Cancer Institute, 1998.
2. Sakr WA, Haas GP, Cassin BF, et al: The frequency of carcinoma and intraepithelial mepithelial neoplasia of the prostate in young male patients [see comments]. J Urol 150:379-385, 1993.
3. Haas GP, Sakr WA: Epidemiology of prostate cancer. CA Cancer J Clin 47:273-287, 1997.
4. Berthon P, Valeri A, Cohen-Akenine A, et al: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62:1416-1424, 1998.
5. Williams BJ, Jones E, Zhu XL, et al: Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer [see comments]. J Urol 155:720-725, 1996.
6. Powell IJ, Heilbrun LK, Sakr W, et al: The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: A multivariate analysis of positive surgical margins. Urology 49:726-731, 1997.
7. Mettiin C, Murphy GP, Lee F, et al: Characteristics of prostate cancers detected in a multimodality, early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer 72:1701-1708, 1993.
8. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer [see comments]. JAMA 273:289-294, 1995.
9. Control DoCPa: PLCO Homepage, vol 1998, National Cancer Institute, 1998.
10. Cooner WH, Mosley BR, Rutherford CL Jr, et al: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146-1152; discussion 1152-1154, 1990.
11. Drawer MK, Chetner MP, Beatie J, et al: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841-845, 1992.
12. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer [published erratum appears in N Engl J Med 1991 Oct 31;325(18):1324] [see comments]. N Engl JMed 324:1156-1161, 1991.
13. Chodak GW, Keller P, Schoenberg HW: Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141:1136-1138, 1989.
14. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men [see comments]. J Urol 151:1283-1290, 1994.
15. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium. Arch Intern Med 155:389-392, 1995.
16. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening [see comments]. JAMA 270:948-954, 1993.
17. Mettlin C, Lee F, Drago J, et al: The American Cancer Society National Prostate Cancer Detection Project: Findings on the detection of early prostate cancer in 2425 men. Cancer 67:2949-2958, 1991.
18. Henderson RJ, Eastham JA, Culkin DJ, et al: Prostate-specific antigen (PSA) and PSA density: Racial differences in men without prostate cancer. J Natl Cancer Inst 89:134-138, 1997.
19. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease [see comments]. JAMA 267:2215-2220, 1992.
20. Smith DS, Catalona WJ: Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection [see comments]. J Urol 152:1163-1167, 1994.
21. Christensson A, Bjork T, Nilsson O, et al: Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150:100-105, 1993.
22. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154:1090-1095, 1995.
23. Labrie F, Dupont A, Candas B, et al: Decrease of Prostate Cancer Death by Screening: First Data from the Quebec Prospective and Randomized Study. Paper presented at the Annual Meeting of the American Society of Clinical Oncology, Los Angeles, 1998.
24. Fowler JE Jr, Bigler SA, Kolski JM, et al: Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 82:1112-1117, 1998.
25. Clark LC, Combs CF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [see comments] (published erratum appears in JAMA 277:1520, 1997). JAMA 276:1957-1963, 1996.
26. Heinonen OP, Albanes D, Virtamo J, et al: Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: Incidence and mortality in a controlled trial [see comments]. JNatl Cancer Inst 90:440-446, 1998.
27. Brawer MK, Bigler SA, Sohlberg CE, et al: Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 38:103-107, 1991.
28. Gleason DF: Histologic grading of clinical staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology: The Prostate. Philadelphia, Lea & Febiger, 1977, pp 171-197.
29. Fukunaga-Johnson N, Sandier HM, McLaughlin PW, et al: Results of 3D conformai radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 38:311-317, 1997.
30. Fleming ID, Cooper JS, Henson DE, et al: Cancer Staging Manual, in Fleming ID CJ, Henson DE, et al (ed): American Joint Committee on Cancer. Cancer Staging Manual. (ed 5). Philadelphia, Lippincott-Raven, 1997, pp 219-224.
31. Lange PH, Narayan P: Understaging and undergrading of prostate cancer: Argument for postoperative radiation as adjuvant therapy. Urology 21:113-118, 1983.
32. Catalona WJ, Bigg SW: Nerve-sparing radical prostatectomy: Evaluation of results after 250 patients. J Urol 143:538-543; discussion 544, 1990.
33. Oesterling JE, Martin SK, Bergstralh EJ, et al: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer [see comments]. JAMA 269:57-60, 1993.
34. Bluestein DL, Bostwick DG, Bergstralh EJ, et al: Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer [see comments]. J Urol 151:1315-1320, 1994.
35. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [see comments] (published erratum appears in JAMA 278:118, 1997). JAMA 277:1445-1451, 1997.
36. Edelstein RA, Zietman AL, de las Morenas A, et al: Implications of prostate micrometastases in pelvic lymph nodes: An archival tissue study. Urology 47:370-375, 1996.
37. Ferrari AC, Stone NN, Eyler JN, et al: Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer [see comments]. J Natl Cancer Inst 89:1498-1504, 1997.
38. Panel AUAPCCG: Report on the Management of Clinically Localized Prostate Cancer: Clinical, Practice Guidelines. Baltimore, Md, American Urological Association, 1995.
39. Johansson JE, Adami HO, Andersson SO, et al: High 10-year survival rate in patients with early, untreated prostatic cancer [see comments]. JAMA 267:2191-2196, 1992.
40. Jones GW: Prospective, conservative management of localized prostate cancer. Cancer 70:307-310, 1992.
41. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized prostate cancer [see comments]. JAMA 274:626-631, 1995.
42. Moore MJ, O'Sullivan B, Tannock IF: How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol 6:1736-1745, 1988.
43. Smart CR: The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 80:1835-1844, 1997.
44. Lepor H, Walsh PC: Long-term results of radical prostatectomy in clinically localized prostate cancer: Experience at the Johns Hopkins Hospital. NCI Monogr 117-122, 1988.
45. Walsh PC: Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Urol 156:301-302, 1996.
46. Oefelein MG, Grayhack JT, McVary KT: Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate [see comments]. Cancer 76:2535-2542, 1995.
47. Gerber GS, Thisted RA, Scardino PT, et al: Results of radical prostatectomy in men with clinically localized prostate cancer [see comments]. JAMA 276:615-619, 1996.
48. Goldenberg SL, Klotz LH, Srigley J, et al: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group. J Urol 156:873-877, 1996.
49. Van Poppel H, De Ridder D, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. The Belgian Uro- Oncological Study Group. J Urol 154:429-434, 1995.
50. Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154:424-428, 1995.
51. Fair WR, Cookson MS, Stroumbakis N, et al: The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49:46-55, 1997.
52. Nguyen LN, Pollack A, Zagars GK: Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 51:991-997, 1998.
53. Beard C J, Lamb C, Buswell L, et al: Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 41:257-262, 1998.
54. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer [see comments]. Int J Radiat Oncol Biol Phys 41:491-500, 1998.
55. Blasko JC, Wallner K, Grimm PD, et al: Prostate specific antigen based disease control following ultrasound guided 125 iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 154:1096-1099, 1995.
56. Stock RG, Stone NN, DeWyngaert JK, et al: Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 77:2386-2392, 1996.
57. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997.
58. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [see comments]. N Engl J Med 337:295-300, 1997.
59. D'Amico AV, Whittington R, Malkowicz SB, et al: Pretreatment nomogram for Prostate-Specific Antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17:168-172, 1999.